These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 12867066)

  • 21. Antisense oligonucleotides: target validation and development of systemically delivered therapeutic nanoparticles.
    Zhang C; Pei J; Kumar D; Sakabe I; Boudreau HE; Gokhale PC; Kasid UN
    Methods Mol Biol; 2007; 361():163-85. PubMed ID: 17172711
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potential roles of antisense oligonucleotides in cancer therapy. The example of Bcl-2 antisense oligonucleotides.
    Dias N; Stein CA
    Eur J Pharm Biopharm; 2002 Nov; 54(3):263-9. PubMed ID: 12445555
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antisense strategies.
    Crooke ST
    Curr Mol Med; 2004 Aug; 4(5):465-87. PubMed ID: 15267220
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oblimersen sodium (G3139 Bcl-2 antisense oligonucleotide) therapy in Waldenstrom's macroglobulinemia: a targeted approach to enhance apoptosis.
    Frankel SR
    Semin Oncol; 2003 Apr; 30(2):300-4. PubMed ID: 12720157
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antisense cancer therapy: the state of the science.
    Kushner DM; Silverman RH
    Curr Oncol Rep; 2000 Jan; 2(1):23-30. PubMed ID: 11122821
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rational design of sequence-specific oncogene inhibitors based on antisense and antigene oligonucleotides.
    Hélène C
    Eur J Cancer; 1991; 27(11):1466-71. PubMed ID: 1835863
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cytotoxicity of etoposide in cancer cell lines in vitro after BCL-2 and C-RAF gene silencing with antisense oligonucleotides.
    Sypniewski D; Bednarek I; Gałka S; Loch T; Błaszczyk D; Sołtysik D
    Acta Pol Pharm; 2013; 70(1):87-97. PubMed ID: 23610963
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A functionally improved locked nucleic acid antisense oligonucleotide inhibits Bcl-2 and Bcl-xL expression and facilitates tumor cell apoptosis.
    Simões-Wüst AP; Hopkins-Donaldson S; Sigrist B; Belyanskaya L; Stahel RA; Zangemeister-Wittke U
    Oligonucleotides; 2004; 14(3):199-209. PubMed ID: 15625915
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bcl-2 antisense in the treatment of human malignancies: a delusion in targeted therapy.
    Gjertsen BT; Bredholt T; Anensen N; Vintermyr OK
    Curr Pharm Biotechnol; 2007 Dec; 8(6):373-81. PubMed ID: 18289046
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of antisense oligonucleotides: advantages, controls, and cardiovascular tissue.
    Golden T; Dean NM; Honkanen RE
    Microcirculation; 2002 Jan; 9(1):51-64. PubMed ID: 11896559
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence.
    Ziegler A; Luedke GH; Fabbro D; Altmann KH; Stahel RA; Zangemeister-Wittke U
    J Natl Cancer Inst; 1997 Jul; 89(14):1027-36. PubMed ID: 9230884
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modulation of lipoprotein metabolism by antisense technology: preclinical drug discovery methodology.
    Crooke RM; Graham MJ
    Methods Mol Biol; 2013; 1027():309-24. PubMed ID: 23912993
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment.
    Klasa RJ; Gillum AM; Klem RE; Frankel SR
    Antisense Nucleic Acid Drug Dev; 2002 Jun; 12(3):193-213. PubMed ID: 12162702
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Using RNA-seq to Assess Off-Target Effects of Antisense Oligonucleotides in Human Cell Lines.
    Michel S; Schirduan K; Shen Y; Klar R; Tost J; Jaschinski F
    Mol Diagn Ther; 2021 Jan; 25(1):77-85. PubMed ID: 33314011
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antisense strategy: biological utility and prospects in the treatment of hematological malignancies.
    Warzocha K; Wotowiec D
    Leuk Lymphoma; 1997 Jan; 24(3-4):267-81. PubMed ID: 9156656
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antisense Oligonucleotide-Based Therapy for Neuromuscular Disease.
    Sardone V; Zhou H; Muntoni F; Ferlini A; Falzarano MS
    Molecules; 2017 Apr; 22(4):. PubMed ID: 28379182
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antisense oligonucleotides directed against p53 have antiproliferative effects unrelated to effects on p53 expression.
    Barton CM; Lemoine NR
    Br J Cancer; 1995 Mar; 71(3):429-37. PubMed ID: 7880719
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antisense therapy for malignant mesothelioma with oligonucleotides targeting the bcl-xl gene product.
    Smythe WR; Mohuiddin I; Ozveran M; Cao XX
    J Thorac Cardiovasc Surg; 2002 Jun; 123(6):1191-8. PubMed ID: 12063468
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antisense oligonucleotides adsorbed to polyalkylcyanoacrylate nanoparticles specifically inhibit mutated Ha-ras-mediated cell proliferation and tumorigenicity in nude mice.
    Schwab G; Chavany C; Duroux I; Goubin G; Lebeau J; Hélène C; Saison-Behmoaras T
    Proc Natl Acad Sci U S A; 1994 Oct; 91(22):10460-4. PubMed ID: 7937975
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Towards genomic drug therapy with antisense oligonucleotides.
    Lönnberg H; Vuorio E
    Ann Med; 1996 Dec; 28(6):511-22. PubMed ID: 9017110
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.